Arzerra, the recently approved monoclonal antibody treatment for leukemia from GlaxoSmithKline and Genmab, will be manufactured by Lonza. The Swiss-based contract manufacturer performed process development and cGMP manufacturing services to support the drug's licensure.
According to Lonza, Arzerra treats chronic lymphocytic leukemia by alerting the immune system to protect B-cells, which become cancerous as a result of the disease. The drug attaches to epitope molecules on the cells' surface.
Separately, Lonza has acquired AlgoNomics NV, a Belgium-based provider of immunogenicity screening services and tools. The AlgoNomics Tripole technology platform supports Lonza's aim to incorporate quality by design at the molecular level, improving the manufacturability of protein-based drugs.
- here's the Arzerra announcement
- read the AlgoNomics release